Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Gold Prices Slide as Iran Conflict Fuels Fed Rate Hike Bets 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Asian Currencies Weaken as Dollar Rises, Kiwi Slides After RBNZ Hike 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Singapore Straits Times Index Hits Record High as Banks, Property Stocks Rally 
South Korea Inflation Rises to 3.1% in August 
Bank of England Sees Surge in Higher-Risk Collateral 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
India Services PMI Rises to 54.1 as Hiring Accelerates 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Gold Prices Hold Near $4,400 as Fed Rate Hike Bets Ease 
Add as a preferred source on Google
Bristol Myers and AbbVie are reportedly planning to terminate some of their staff in California. The job cuts will be the latest in a string of layoffs in the biopharma industry in the United States.
As per Reuters, a combined total of 360 job roles are set to be affected by the plan. Both Bristol Myers Squibb Co, and AbbVie Inc. reportedly informed the officials of the California administration that they will eliminate some of their employees.
The notices were said to have been filed last week with the state but were only made public a few days after. In the filing, Bristol Myers Squibb indicated that it will remove up to 261 jobs in its offices in two locations in San Diego, California. As of AbbVie, it told the state it will be slashing some 99 jobs in Irvine.
The company’s spokesman said that the layoffs at Bristol Myers are taking place after the company acquired Turning Point Therapeutics Inc. for $4.1 billion. The biopharma’s acquisition deal with the San Diego-based biotech drug developer closed just last month.
Fierce Pharma reported that the job cut notices were separately filed by Bristol Myers and AbbVie under the Worker Adjustment and Retraining Notification (WARN) alerts. The filing is to officially inform California that there will be layoffs from their companies this November.
With the move, Bristol Myers and AbbVie have joined other major biopharmaceutical firms such as Novartis and Biogen in the reduction of their workforce. At any rate, BMS’s job cuts are related to its latest acquisition deal of Turning Point Therapeutics and this was confirmed by the company through its spokesman.
“We are very pleased to have completed the acquisition of Turning Point Therapeutics to further strengthen our leading oncology franchise,” the company said in a separate statement. “As part of the integration, all incoming employees received retention packages tied to continued service to BMS for a period of time and have been encouraged to apply to long-term roles at BMS after their retention period ends.”
Meanwhile, AbbVie was not able to respond immediately to a request for comment regarding the job cuts.
